The effect of high‐dose methotrexate on renal tubules as indicated by urinary lysozyme concentration

Lysozyme was measured after 186 doses of methotrexate (MTX) to 88 patients. After 7.5% of the doses, lysozyme rose to between 2 and 19 m̈g/cc and in 3.2% it rose to between 20 and 120 m̈g/cc. These increases had no relationship to the age of the patients, their dose of MTX, the total number of times that MTX had been given, nor to rises in serum creatinine. It did correlate with the administration of aminoglycosides (a part of the supportive care of these patients) in two thirds of these cases. In the patients who did not receive aminoglycosides, no urinary lysozyme concentration rose above 19 m̈g/cc, not even in the patients who became oliguric or required hemoperfusion. Most of these rises occurred early and were of 24 to 48 hour duration. The rises occurring after five days were persistent and were associated with prolonged MTX serum concentrations, suggesting that tubular damage due to MTX was the result of prolonged exposure to MTX, rather than the primary cause of kidney damage, i.e., the event causing the prolonged serum concentrations.

[1]  J. Herson,et al.  Evaluation of overall toxicity of high-dosage methotrexate regimens. , 1979, Medical and pediatric oncology.

[2]  T. Lehner,et al.  Immunological aspects of recurrent oral ulceration and Behçet's syndrome. , 1978, Journal of oral pathology.

[3]  J. Legros Urinary excretion of neurophysins in patients with kidney disease. , 1978, The Journal of endocrinology.

[4]  G. Neale,et al.  Serum and faecal lysozyme in inflammatory bowel disease. , 1978, Gut.

[5]  Jerome J. Schentag,et al.  Early detection of aminoglycoside nephrotoxicity with urinary beta-2-microglobulin. , 1978, Journal of medicine.

[6]  M. Irving,et al.  Methotrexate megadose followed by folate rescue. II. Clearance patterns in patients receiving sequential megadose infusions. , 1976, The Medical journal of Australia.

[7]  D. Lovell,et al.  Renal damage caused by gentamicin: A study of the effects on renal morphology and urinary enzyme excretion , 1976, The Journal of pathology.

[8]  B. Chabner,et al.  7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. , 1976, The Journal of clinical investigation.

[9]  A. Evan,et al.  The effects of sodium chromate on the proximal tubules of the rat kidney. Fine structural damage and lysozymuria. , 1974, Laboratory investigation; a journal of technical methods and pathology.

[10]  J. Wauters,et al.  [Urine lysozyme determination as a diagnostic tool in nephropathies]. , 1970, Schweizerische medizinische Wochenschrift.

[11]  H. Baker Some hazards of methotrexate treatment of psoriasis. , 1970, Transactions of the St. John's Hospital Dermatological Society.

[12]  R G Adams,et al.  The development of cadmium-induced proteinuria, impaired renal function, and osteomalacia in alkaline battery workers. , 1969, The Quarterly journal of medicine.

[13]  F. Morgenthaler,et al.  Methotrexate excretion patterns and renal toxicity after intravenous injection or arterial infusion. , 1969, Archives of surgery.

[14]  T. Ryan,et al.  SYSTEMIC CONRTICOSTEROIDS AND FOLIC ACID ANATONISTS IN THE TREATMENT OF GENRALIZED PUSTULAR PSOBLASIS EVALUATION AND PROGNOSIS BASED ON THE STUDY OF 104 CASES , 1969, The British journal of dermatology.

[15]  R. E. Chanes,et al.  Renal toxicity of methotrexate , 1969, Cancer.

[16]  J. Hayslett,et al.  Urinary muramidase and renal disease. Correlation with renal histology and implication for the mechanism of enzymuria. , 1968, The New England journal of medicine.

[17]  J. Blainey,et al.  Urinary lysozyme, ribonuclease, and low-molecular-weight protein in renal disease. , 1968, Lancet.

[18]  S. Finch,et al.  Studies of Muramidase (Lysozyme) in Leukemia , 1968 .

[19]  H. Fudenberg,et al.  Leukocyte lysozyme activity in myelocytic leukemia. , 1967, Blood.

[20]  A. Mckenzie,et al.  The Editor, ‘The British Journal of Dermatology’. Psoriasis and folic acid antagonists. , 1967 .

[21]  H. R. Vickers,et al.  Psoriasis and folic acid antagonists , 1966 .

[22]  E. Osserman,et al.  SERUM AND URINARY LYSOZYME (MURAMIDASE) IN MONOCYTIC AND MONOMYELOCYTIC LEUKEMIA , 1966, The Journal of experimental medicine.

[23]  D. Prockop,et al.  A STUDY OF URINARY AND SERUM LYSOZYME IN PATIENTS WITH RENAL DISEASE. , 1964, The New England journal of medicine.

[24]  G. Litwack Photometric Determination of Lysozyme Activity.∗ † , 1955, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[25]  R. Vilter Treatment of macrocytic anemias. , 1955, A.M.A. archives of internal medicine.